首页> 美国卫生研究院文献>Annals of Surgery >Experience with 647 consecutive tumors of the duodenum ampulla head of the pancreas and distal common bile duct.
【2h】

Experience with 647 consecutive tumors of the duodenum ampulla head of the pancreas and distal common bile duct.

机译:经历过647例十二指肠壶腹胰头和远端胆总管的连续肿瘤。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Between 1946 and 1987, 647 patients with periampullary tumors were diagnosed at the University of Chicago Medical Center. These included 549 tumors located in the head of the pancreas, 40 in the distal common bile duct, 29 in the duodenum, and 29 at the ampulla of Vater. Ninety-eight per cent of all tumors were adenocarcinoma, with 93% of the remaining being duodenal carcinoid or sarcoma. Operability rate ranged from 81% to 97%, according to the tumor location and histologic type. A combination of laparotomy, biopsy, and bypass was performed in 433 patients and only one survived 5 years (0.2%). Resectability rate ranged from 16.5% for pancreatic adenocarcinoma to 89.3% for ampullary tumors. Of the 133 resections, 80 were pancreatoduodenectomies, 29 total pancreatectomies, 7 duodenectomies, 2 gastrectomies, 8 common bile duct resections, and 7 local excisions. Overall 19% of patients who underwent radical resection died in the immediate postoperative period, although mortality has decreased to 5% since 1981. Mortality was 20% after a standard pancreatoduodenectomy and 24.1% after a total pancreatectomy. Five-year actuarial survival rates, including perioperative deaths, were 8.8%, 20%, and 32% for pancreatic, duodenal, and ampullary adenocarcinoma, respectively. One half of patients with sarcoma and two-thirds with carcinoid of the duodenum survived 5 years. No patient with distal common bile duct adenocarcinoma achieved a 5-year survival rate. Multivariate analysis on all patients operated on (n = 566) revealed that the 5-year survival rate was significantly related to intent of operation (palliative 0.2%, curative 12%; p less than 0.001), histologic type (adenocarcinoma 2%, carcinoid and sarcoma 31%; p less than 0.0001), and site (ampullary and duodenal 21%, biliary and pancreatic 0.9%; p less than 0.001). A second multivariate analysis, evaluating only those patients with adenocarcinoma who survived the perioperative period of the radical resection (n = 97) analyzed the influence of tumor size and differentiation, lymphatic, capillary, and perineural microinvasion, lymph node status, and type of procedure (pancreatoduodenectomy vs. total pancreatectomy) on 5-year survival. None of these additional variables was significantly associated with long-term survival rates. In addition we evaluated the presence of local or distant recurrence after resection by analyzing the findings from all autopsies performed on these patients (n = 49): 29.4% of patients died with local recurrence alone, 23.5% with distant recurrence alone, and 47.1% had both local and distant recurrences.(ABSTRACT TRUNCATED AT 400 WORDS)
机译:在1946年至1987年之间,芝加哥大学医学中心诊断出647例壶腹周围肿瘤患者。其中包括位于胰头的549例肿瘤,远端胆总管的40例,十二指肠的29例和Vater壶腹的29例。在所有肿瘤中,有98%为腺癌,其余93%为十二指肠类癌或肉瘤。根据肿瘤的位置和组织学类型,可手术率范围为81%至97%。 433例患者进行了剖腹,活检和搭桥手术,仅1例存活5年(0.2%)。可切除率范围从胰腺腺癌的16.5%到壶腹肿瘤的89.3%。在133例切除术中,有80例行胰十二指肠切除术,29例行全胰切除术,7例十二指肠切除术,2例胃切除术,8例胆总管切除术和7例局部切除术。总体上,接受根治性切除术的患者中有19%在术后立即死亡,尽管自1981年以来死亡率已降至5%。标准的胰十二指肠切除术后的死亡率为20%,全胰切除术后的死亡率为24.1%。胰腺癌,十二指肠癌和壶腹腺癌的五年精算生存率(包括围手术期死亡)分别为8.8%,20%和32%。肉瘤患者的一半和十二指肠类癌的患者的三分之二生存了5年。没有远端胆总管腺癌患者达到5年生存率。对所有接受手术治疗的患者(n = 566)进行多因素分析表明,其5年生存率与手术意图(姑息0.2%,治愈12%; p小于0.001),组织学类型(腺癌2%,类癌)显着相关。肉瘤为31%; p小于0.0001)和部位(壶腹和十二指肠为21%,胆胰脏为0.9%; p小于0.001)。第二次多变量分析仅评估那些在根治性切除术围手术期幸存下来的腺癌患者,分析了肿瘤大小和分化,淋巴,毛细血管和神经周围微浸润,淋巴结状况以及手术类型的影响(胰十二指肠切除术与全胰切除术)的5年生存率。这些附加变量均未与长期生存率显着相关。此外,我们通过分析对这些患者进行的所有尸检的结果来评估切除后是否存在局部或远处复发(n = 49):29.4%的患者仅因局部复发而死亡,23.5%的患者仅因远处复发而死亡,47.1%既有局部又有远处的复发(摘要截短了400字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号